Analysis of human exposure to landslides with a GIS multiscale approach

Decision-making plays a key role in reducing landslide risk and preventing natural disasters. Land management, recovery of degraded lands, urban planning, and environmental protection in general are fundamental for mitigating landslide hazard and risk. Here, we present a GIS-based multi-scale approach to highlight where and when a country is affected by a high probability of landslide occurrence. In the first step, a landslide human exposure equation is developed considering the landslide susceptibility triggered by rain as hazard, and the population density as exposed factor. The output, from this overview analysis, is a global GIS layer expressing the number of potentially affected people by month, where the monthly rain is used to weight the landslide hazard. As following step, Logistic Regression (LR) analysis was implemented at a national and local level. The Receiver Operating Characteristic indicator is used to understand the goodness of a LR model. The LR models are defined by a dependent variable, presence–absence of landslide points, versus a set of independent environmental variables. The results demonstrate the relevance of a multi-scale approach, at national level the biophysical variables are able to detect landslide hotspot areas, while at sub-regional level geomorphological aspects, like land cover, topographic wetness, and local climatic condition have greater explanatory power.

Nanoparticle-Based Modification of the DNA Methylome: A Therapeutic Tool for Atherosclerosis?

Cardiovascular epigenomics is a relatively young field of research, yet it is providing novel insights into gene regulation in the atherosclerotic arterial wall. That information is already pointing to new avenues for atherosclerosis (AS) prevention and therapy. In parallel, advances in nanoparticle (NP) technology allow effective targeting of drugs and bioactive molecules to the vascular wall. The partnership of NP technology and epigenetics in AS is just beginning and promises to produce novel exciting candidate treatments. Here, we briefly discuss the most relevant recent advances in the two fields. We focus on AS and DNA methylation, as the DNA methylome of that condition is better understood in comparison with the rest of the cardiovascular disease field. In particular, we review the most recent advances in NP-based delivery systems and their use for DNA methylome modification in inflammation. We also address the promises of DNA methyltransferase inhibitors for prevention and therapy. Furthermore, we emphasize the unique challenges in designing therapies that target the cardiovascular epigenome. Lastly, we touch the issue of human exposure to industrial NPs and its impact on the epigenome as a reminder of the undesired effects that any NP-based therapy must avoid to be apt for secondary prevention of AS.